Second-Gen Drug for HCM Emerges, Nipping at Mavacamten’s Heels
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of treatment with aficamten brought resting left ventricular outflow tract (LVOT) gradients down significantly compared with placebo before a 2-week washout period returned gradients to baseline, reported Martin […]